Literature DB >> 19729213

BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status.

Joana Pimenta1, Cristiana Paulo2, Joana Mascarenhas2, André Gomes3, Ana Azevedo4, Francisco Rocha-Gonçalves5, Paulo Bettencourt2.   

Abstract

BACKGROUND: Besides hemodynamic parameters, several other variables have been associated to B-type natriuretic peptide (BNP) levels. Limited knowledge on BNP determinants in acute heart failure (HF) can undermine the interpretation of BNP levels. METHODS AND
RESULTS: To identify predictors of BNP levels, we evaluated 163 hospitalized acute HF patients. Thoracic fluid content (TFC) and hemodynamic parameters were measured by impedance cardiography at discharge. Patients were followed-up for 60 days for the occurrence of death/hospital admission. Median discharge BNP levels were 659.3 pg/ml. In multivariable linear regression analysis, TFC (β=0.043, 95% CI 0.024-0.062 per U/kΩ, p<0.001) was a powerful predictor of BNP levels, independently of known markers of HF severity like severe systolic dysfunction and discharge New York Heart Association class. Other independent predictors were: new onset HF, albumin, and body mass index. Sex, left cardiac work index, stroke index, hemoglobin, renal failure and discharge furosemide and lisinopril doses were associated to BNP only in univariate analysis. During follow-up, 45 (27.6%) patients were hospitalized or died. TFC (HR=1.047 (1.016-1.080) per U/kΩ increase, p=0.003) and BNP (HR=1.003 (1.001-1.004) per 10 pg/ml increase, p<0.001) were univariate predictors of the outcome, but in multivariate Cox regression analysis, only BNP was independently associated with prognosis.
CONCLUSION: Discharge BNP levels in acute HF patients reflected volemia and disease severity. Persistently high BNP levels during hospitalization should raise the possibility of remaining congestion, which could negatively influence prognosis. The utility of BNP as prognostic marker in HF may reside on its ability to reflect multiple underlying pathophysiological disturbances.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729213     DOI: 10.1016/j.ijcard.2009.08.001

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  16 in total

1.  Seeking new approaches: milrinone in the treatment of cerebral vasospasm.

Authors:  Antoine Baumann; Anne-Laure Derelle; Paul-Michel Mertes; Gérard Audibert
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

Review 2.  BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review.

Authors:  Pasqualina L Santaguida; Andrew C Don-Wauchope; Mark Oremus; Robert McKelvie; Usman Ali; Stephen A Hill; Cynthia Balion; Ronald A Booth; Judy A Brown; Amy Bustamam; Nazmul Sohel; Parminder Raina
Journal:  Heart Fail Rev       Date:  2014-08       Impact factor: 4.214

3.  Redefining Cirrhotic Cardiomyopathy for the Modern Era.

Authors:  Manhal Izzy; Lisa B VanWagner; Grace Lin; Mario Altieri; James Y Findlay; Jae K Oh; Kymberly D Watt; Samuel S Lee
Journal:  Hepatology       Date:  2019-10-11       Impact factor: 17.425

4.  Worsening renal function is not associated with response to treatment in acute heart failure.

Authors:  Sameer Ather; Chirag Bavishi; Mark D McCauley; Amandeep Dhaliwal; Anita Deswal; Sarah Johnson; Wenyaw Chan; David Aguilar; Allison M Pritchett; Kumudha Ramasubbu; Xander H T Wehrens; Biykem Bozkurt
Journal:  Int J Cardiol       Date:  2012-05-25       Impact factor: 4.164

Review 5.  Biomarkers in acute heart failure--state of the art.

Authors:  Alan S Maisel; Rajiv Choudhary
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

6.  Mineralocorticoid Receptor Antagonism in Acute Heart Failure.

Authors:  Kemar Brown; Jennifer Chee; Stella Kyung; Bicky Vettichira; Lampros Papadimitriou; Javed Butler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-09

7.  Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.

Authors:  Javed Butler; Adrian F Hernandez; Kevin J Anstrom; Andreas Kalogeropoulos; Margaret M Redfield; Marvin A Konstam; W H Wilson Tang; G Michael Felker; Monica R Shah; Eugene Braunwald
Journal:  JACC Heart Fail       Date:  2016-08-10       Impact factor: 12.035

Review 8.  Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin.

Authors:  Alberto Palazzuoli; Serge Masson; Claudio Ronco; Alan Maisel
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

9.  Fluid overload at start of continuous renal replacement therapy is associated with poorer clinical condition and outcome: a prospective observational study on the combined use of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretic peptide measurement.

Authors:  Haiyan Chen; Buyun Wu; Dehua Gong; Zhihong Liu
Journal:  Crit Care       Date:  2015-04-02       Impact factor: 9.097

10.  B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes.

Authors:  Kelsey M Flint; Larry A Allen; Michael Pham; Paul A Heidenreich
Journal:  J Am Heart Assoc       Date:  2014-06-10       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.